Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial for edasalonexent is enrolling boys affected by Duchenne .

Catabasis Pharmaceuticals

Type	Public
Traded as	NASDAQ: CATB Russell Microcap Index component
Industry	Pharmaceuticals
Founded	2008
Headquarters	Cambridge, Massachusetts
Key people	Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer) Andrew Nichols, Ph.D. (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer)
Products	Orally-delivered pharmaceuticals
Number of employees	24 (March 2019)
Website	www.catabasis.com

In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values .

In January 2020, Catabasis announced the pricing of an underwritten public offering of 4,600,000 shares of common stock priced at $5.00 per share. The gross proceeds are expected to be approximately $23 million, before deducting the underwriting discount and other offering expenses.[2][3]